The challenge
Inbeeo’s client entered a due diligence (DD) process to acquire the rights to commercialise a novel specialty drug candidate in Europe. This candidate, an established molecule, was undergoing a Phase III trial for repurposing in an orphan indication.
As part of the DD, the client required a comprehensive analysis, including insights into the potential target population size, pricing potential, and overall commercial viability.
Given the competitive nature of the bidding, it was critical to deliver the payer insights report within four weeks of the project kick-off to align with the broader due diligence timeline.
The approach
To develop the most accurate estimates within the due diligence timelines, Inbeeo employed a triangulated approach, leveraging multiple data sources:
- Desk research, to gather data from e..g, Orphanet and US NIH databases to gain a high-level, comparative, disease overview
- A targeted literature review, to synthesize all available information on incidence, prevalence and disease staging
- Clinical expert centre insights, on the burden of disease and estimated patient numbers – leveraging Inbeeo’s expert network
- Key opinion leader (KOL) interviews, with top tier clinical KOLs across markets (selected for their extensive experience) to map the potential patient waterfall and product placement within the treatment algorithm.
- Payer interviews, with payer experts (2-3 per market) to validate assumptions around pricing, reimbursement, and market access feasibility.
The impact
The findings were consolidated into detailed reports and executive summaries, offering actionable strategic recommendations across key areas:
- Pricing estimates
- Reimbursement expectations
- Launch sequence planning
- Commercial opportunity assessment
Inbeeo successfully delivered the project on time and within budget. The insights and strategic guidance ultimately supported a ‘GO’ decision, enabling the client to acquire the rights to commercialize this promising asset. Subsequently, Inbeeo supported the development of in-market pricing and reimbursement preparations. The product is currently achieving pricing and reimbursement in the major European markets.
